Molecular Data Stock Net Income
| MKDTY Stock | USD 0.0001 0.00 0.00% |
As of the 14th of February 2026, Molecular Data secures the Risk Adjusted Performance of 0.0857, mean deviation of 7.97, and Standard Deviation of 24.65. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Molecular Data, as well as the relationship between them.
Molecular Data's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Molecular Data's valuation are provided below:Molecular Data does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Molecular |
Molecular Data 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Molecular Data's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Molecular Data.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Molecular Data on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Molecular Data or generate 0.0% return on investment in Molecular Data over 90 days. Molecular Data is related to or competes with Kemira Oyj, Clariant, Kansai Paint, Azelis Group, and Navigator Company. More
Molecular Data Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Molecular Data's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Molecular Data upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0914 | |||
| Maximum Drawdown | 216.67 |
Molecular Data Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Data's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Molecular Data's standard deviation. In reality, there are many statistical measures that can use Molecular Data historical prices to predict the future Molecular Data's volatility.| Risk Adjusted Performance | 0.0857 | |||
| Jensen Alpha | 2.13 | |||
| Total Risk Alpha | 0.4824 | |||
| Treynor Ratio | 0.7779 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Data's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Molecular Data February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0857 | |||
| Market Risk Adjusted Performance | 0.7879 | |||
| Mean Deviation | 7.97 | |||
| Coefficient Of Variation | 1060.92 | |||
| Standard Deviation | 24.65 | |||
| Variance | 607.51 | |||
| Information Ratio | 0.0914 | |||
| Jensen Alpha | 2.13 | |||
| Total Risk Alpha | 0.4824 | |||
| Treynor Ratio | 0.7779 | |||
| Maximum Drawdown | 216.67 | |||
| Skewness | 3.91 | |||
| Kurtosis | 24.14 |
Molecular Data Backtested Returns
Molecular Data is out of control given 3 months investment horizon. Molecular Data has Sharpe Ratio of 0.0965, which conveys that the firm had a 0.0965 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for sixteen different technical indicators, which can help you to evaluate if expected returns of 2.43% are justified by taking the suggested risk. Use Molecular Data Risk Adjusted Performance of 0.0857, mean deviation of 7.97, and Standard Deviation of 24.65 to evaluate company specific risk that cannot be diversified away. Molecular Data holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 2.97, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Molecular Data will likely underperform. Use Molecular Data variance and rate of daily change , to analyze future returns on Molecular Data.
Auto-correlation | -0.42 |
Modest reverse predictability
Molecular Data has modest reverse predictability. Overlapping area represents the amount of predictability between Molecular Data time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Molecular Data price movement. The serial correlation of -0.42 indicates that just about 42.0% of current Molecular Data price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.42 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Molecular Data reported net income of 0.0. This is 100.0% lower than that of the Basic Materials sector and 100.0% lower than that of the Chemicals industry. The net income for all United States stocks is 100.0% higher than that of the company.
Molecular Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Data's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Data could also be used in its relative valuation, which is a method of valuing Molecular Data by comparing valuation metrics of similar companies.Molecular Data is currently under evaluation in net income category among its peers.
About Molecular Data Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Data's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Data using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Data based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Molecular Pink Sheet Analysis
When running Molecular Data's price analysis, check to measure Molecular Data's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Data is operating at the current time. Most of Molecular Data's value examination focuses on studying past and present price action to predict the probability of Molecular Data's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Data's price. Additionally, you may evaluate how the addition of Molecular Data to your portfolios can decrease your overall portfolio volatility.